Sugi Predict

Sugi Predict / Compounds / SCHEMBL1242684

SCHEMBL1242684

SCHEMBL1242684

CC(C)(C)OC(=O)N1C[CH]C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ NR1H2 P55055 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.41
▸ PREP P48147 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ESR2 Q92731 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27001783 0.92 USP2 (0.46) USP2SMN1; SMN2NR1H2MAPK1HPGD
SCHEMBL2496477 0.86 USP2 (0.52) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL222920 0.86 PREP (0.53) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL294179 0.84 USP2 (0.50) USP2SMN1; SMN2NR1H2MAPK1HPGD
SCHEMBL833441 0.81 HPGD (0.47) USP2SMN1; SMN2HPGDGPR119PREP
SCHEMBL4504907 0.79 HPGD (0.50) USP2SMN1; SMN2HPGDGPR119PREP
SCHEMBL293626 0.78 USP2 (0.58) USP2SMN1; SMN2HPGDGPR119MEN1
SCHEMBL698803 0.78 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL18294 0.78 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDGPR119
SCHEMBL25250236 0.77 USP2 (0.56) USP2SMN1; SMN2HPGDGPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024147125-A1 CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-07-11 — — WO claimed
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2024-05-02 — — US claimed
EP-4248965-A2 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-09-27 — — EP claimed
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 — — US claimed
EP-3676297-B1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2023-05-17 — — EP claimed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 — — CN claimed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 — — US claimed
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 — — US claimed
WO-2021062245-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE EXELIXIS, INC. (US) 2021-04-01 — — WO claimed
EP-3768660-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 Denali Therapeutics Inc. (US) 2021-01-27 — — EP claimed
US-8232269-B2 Amide compounds useful in therapy PFIZER INC. (US) 2012-07-31 — — US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP claimed
EP-2350017-A1 AMIDE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2011-08-03 — — EP claimed
WO-2011073269-A1 PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS EVOTEC AG (DE) 2011-06-23 — — WO claimed
WO-2011073276-A1 BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS EVOTEC AG (DE) 2011-06-23 — — WO claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 — — WO claimed
US-20100249091-A1 Amide Compounds Useful in Therapy GIBSON KARL RICHARD 2010-09-30 — — US claimed
WO-2010032200-A1 AMIDE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2010-03-25 — — WO claimed
US-7482456-B2 antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol MERCK FROSST CANADA 2009-01-27 — — US claimed
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors MERCK FROSST CANADA & CO. (CA) 2006-10-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249091-A1 Amide Compounds Useful in Therapy PTGER3, PTGER1, PTGER2 USP2 2697/4885SMN1; SMN2 2735/4885NR1H2 36/4885
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 USP2 1730/4885SMN1; SMN2 1125/4885NR1H2 2351/4885
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 USP2 1730/4885SMN1; SMN2 1125/4885NR1H2 2351/4885
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors PDE4A, PDE4B, PDE3B USP2 1614/4885SMN1; SMN2 3845/4885NR1H2 2007/4885
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 USP2 1730/4885SMN1; SMN2 1125/4885NR1H2 2351/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E USP2 3155/4885SMN1; SMN2 1096/4885NR1H2 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.